Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Correlation of functional and structural outcomes with serum antibody profiles in neovascular AMD treated with ranibizumab
2013-003352-20Phase 4Completed
- Sponsor
- University Medical Center Mainz
- Start
- May 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by University Medical Center Mainz. Primary endpoint: Change in best-corrected visual acuity (BCVA) at Week 12. Started May 2016; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2013-003352-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003352-20.